Th2 and Tc2 Cells in the Regulation of GVHD, GVL, and Graft Rejection: Considerations for the Allogeneic Transplantation Therapy of Leukemia and Lymphoma

References

• Singhal S., Powles R., Trekaven J., Kulkami S., Horton C., Mehta J. Long-term outcome of adult acute leukemia patients who are alive and well two years after allogeneic bone marrow transplantation from an HLA- identical sibling. Leukemia Lymphoma 1995; 34(3–4)287–94
   Google Scholar
• Bensinger W. I., Buckner D., Gahrton G. Allogeneic stem cell transplantation for multiple myeloma. Hematology Oncology Clinics of North America 1997; 11(1)147–57
   PubMed Web of Science ®Google Scholar
• Pavletic Z. S., Bishop M. R., Bierman P. J., Armitage J. O. Bone marrow transplantation in chronic lymphocytic leukemia and lymphomas. Biomedical Pharmacotherapy 1996; 50(3–4)118–24
   PubMed Web of Science ®Google Scholar
• Petersdorf E., Anasetti C, Servida P., Martin P., Hansen J. Effect of HLA matching on outcome of related and unrelated donor transplantation therapy for chronic myelogenous leukemia. Hematology Oncology Clinics of North America 1998; 12(1)107–21
   PubMed Web of Science ®Google Scholar
• Aversa R, Terenzi A., Carotti A., Felicini R., Jacucci R., Zei T., Latini P., Aristei C., Santucci A., Martelli M. P., Cunningham I., Reisner Y., Martelli M. F. Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia. Journal of Clinical Oncology 1999; 17(5)1545–50
   PubMed Web of Science ®Google Scholar
• Lamparelli T., Van Lint M. T., Gualandi E, Occhini D., Barbanti M., Sacchi N., Ficai R, Ghinatti C., Ferrara G. B., Delfino L., Pozzi S., Morabito A., Zikus P., Vitale V., Coruo R., Frassoni F., Bacigalupo A. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience. Bone Marrow Transplantation 1997; 20(12)1057–62
   PubMed Web of Science ®Google Scholar
• Kolb H. J., Mittermuller J., Clemm C., Holler E., Ledderose G., Brehm G., Heim M., Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462–2465
   PubMed Web of Science ®Google Scholar
• Porter D. L., Roth M. S., Lee S. J., McGarigle C., Ferrara J. L., Antin J. H. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplantation 1996; 18: 975–980
   PubMed Web of Science ®Google Scholar
• Porter D. L., Roth M. S., McGarigle C., Ferrara J. L., Antin J. H. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. New England Journal of Medicine 1994; 330(2)100–6
   PubMed Web of Science ®Google Scholar
• Mandigers C. M., Meijerink J. P., Raemaekers J. M., Schattenberg A. V., Mensink E. J. Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18) [letter]. Lancet 1998; 352(9139)1522–3
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V., Uberti J., Karanes C., Abella E., Lum L. G., Momin R., Cummings G., Sensenbrenner L. L. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050–1055
   PubMed Web of Science ®Google Scholar
• Tricot G., Vesole D. H., Jagannath S., Hilton J., Munshi N., Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87(3)1196–8
   PubMed Web of Science ®Google Scholar
• Kolb H. J. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties. Vox Sanguinis 1998; 2: 321–9
   Google Scholar
• Collins R. H., Jr., Shpilberg O., Drobyski W. R., Porter D. L., Giralt S., Champlin R., Goodman S. A., Wolff S. N., Hu W., Verfaillie C, List A., Dalton W., Ognoskie N., Chetrit A., Antin J. H., Nemunaitis J. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation [see comments]. Journal of Clinical Oncology 1997; 15(2)433–44
   PubMed Web of Science ®Google Scholar
• Poynton C. H. T cell depletion in bone marrow transplantation. Bone Marrow Transplantation 1988; 3: 265–279
   PubMed Web of Science ®Google Scholar
• Quinones R. R., Gutierrez R. H., Dinndorf P. A., Gress R. E., Ney A. B., Taylor B., Karandish S., Carter C. S., Luban N. L., Reaman G. H. Extended-cycle elutriation to adjust T-cell content in HLA-disparate bone marrow transplantation. Blood 1993; 82: 307–317
   PubMed Web of Science ®Google Scholar
• Champlin R., Gajewski J., Feig S., Giorgi J., Lyddane N., Lee K., Schmidt I., Winston D., Ho W., Reichert T. Selective depletion of CD8 positive T-lymphocytes for prevention of graft-versus-host disease following allogeneic bone marrow transplantation. Transplant Proceedings 1989; 21: 2947–2948
   PubMed Web of Science ®Google Scholar
• Bordignon C., Bonini C., Verzeletti S., Nobili N., Maggioni D., Traversari C., Giarazzi R., Servida P., Zappone E., Benazzi E. Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Human Gene Therapy 1995; 6: 813–819
   PubMed Web of Science ®Google Scholar
• Mosmann T. R., Cherwinski H., Bond M. W., Giedlin M. A., Coffman R. L. Two types of murine helper T cell clone. 1. Definition according to profiles of lymphokine activities and secreted proteins. Journal of Immunology 1986; 136: 2348–2357
   PubMed Web of Science ®Google Scholar
• Sad S., Mosmann T. R. Single IL-2-Secreting Precursor CD4 T cell Can Develop into either Thl or Th2 Cytokine Secretion Phenotype. Journal of Immunology 1994; 153: 3514–3522
   PubMed Web of Science ®Google Scholar
• Sad S., Marcotte R., Mosmann T. R. Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Thl or Th2 cytokines. Immunity 1995; 2: 271–279
   PubMed Web of Science ®Google Scholar
• Croft M., Carter L., Swain S. L., Dutton R. W. Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. Journal of Experimental Medicine 1994; 180: 1715–1728
   PubMed Web of Science ®Google Scholar
• Powrie E, Correa-Oliveira R., Mauze S., Coffman R. L. Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. Journal of Experimental Medicine 1994; 179: 589–600
   PubMed Web of Science ®Google Scholar
• Sher A., Gazzinelli R. T., Oswald L. P., Clerici M., Kullberg M., Pearce E. J., Berzofsky J. A., Mosmann T. R., James S. L., Morse H. C., Shearer G. M. Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunology Reviews 1992; 127: 183–204
   PubMed Web of Science ®Google Scholar
• Romagnani S. Lymphokine production by human T cells in disease states. Annual Review of Immunology 1994; 12: 227–257
   PubMed Web of Science ®Google Scholar
• Ferrara J. L., Abhyankar S., Gilliland D. G. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. Transplant Proceedings 1993; 25: 1216–1217
   PubMed Web of Science ®Google Scholar
• Schwarer A. P., Jiang Y. Z., Brookes P A., Barrett A. J., Batchelor J. R., Goldman J. M., Lechler R. I. Frequency of anti-recipient alloreactive helper T-cell precursors in donor blood and graft-versus-host disease after HLA-identical sibling bone-marrow transplantation. Lancet 1994; 341: 203–205
   Web of Science ®Google Scholar
• Ramsdell F., Seaman M. S., Miller R. E., Picha K. S., Kennedy M. K., Lynch D. H. Differential ability of Thl and Th2 T cells to express Fas ligand and to undergo activation-induced cell death. International Immunology 1994; 6: 1545–1553
   PubMed Web of Science ®Google Scholar
• Baker M. B., Riley R. L., Podack E. R., Levy R. B. Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fasligand function, but not perforin function. Proceedings of the National Academy of Sciences, USA 1997; 94(4)1366–71
   PubMed Web of Science ®Google Scholar
• Braun M. Y., Lowin B., French L., Acha-Orbea H., Tschopp J. Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. Journal of Experimental Medicine 1996; 183: 657–661
   PubMed Web of Science ®Google Scholar
• Das H., Imoto S., Murayama T, Kajimoto K., Sugimoto T., Isobe T., Nakagawa T., Nishimura R., Kuizumi T. Levels of soluble FasL and FasL gene expression during the development of graft-versus-host disease in DLT-treated patients. British Journal of Haematology 1999; 104(4)795–800
   PubMed Web of Science ®Google Scholar
• Kanda Y., Tanaka Y, Shirakawa K., Yatomi T., Nakamura N., Kami M., Saito T, Izutsu K., Asai T., Yuji K., Ogawa S., Honda H., Mitani K., Chiba S., Yazaki Y., Hirai H. Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease. Bone Marrow Transplantation 1998; 22(8)751–4
   PubMed Web of Science ®Google Scholar
• Sher A., Fiorentino D., Caspar P., Pearce E., Mosmann T. Production of IL-10 by CD4+ T lymphocytes correlates with down-regulation of Thl cytokine synthesis in helminth infection. Journal of Immunology 1991; 147: 2713–2716
   PubMed Web of Science ®Google Scholar
• Oswald L P, Wynn T. A., Sher A., James S. L. Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor alpha required as a costimulatory factor for interferon gamma-induced activation. Proceedings of the National Academy of Sciences, U.S.A. 1992; 89: 8676–8680
   PubMed Web of Science ®Google Scholar
• Bogdan C., Nathan C. Modulation of macrophage function by transforming growth factor beta, inter-leukin-4, and interleukin-10. Annals of the N.Y. Academy of Sciences 1993; 685: 713–739
   PubMed Web of Science ®Google Scholar
• Korngold R. Lethal graft-versus-host disease in mice directed to multiple minor histocompatibility antigens: features of CD8+ and CD4+ T cell responses. Bone Marrow Transplantation 1992; 9: 355–364
   PubMed Web of Science ®Google Scholar
• Carter L. L., Dutton R. W. Relative perforin- and Fas-mediated lysis in T1 and T2 CD8 effector populations. Journal of Immunology 1995; 155: 1028–1031
   PubMed Web of Science ®Google Scholar
• Lin T., Brunner T., Tietz B., Madsen J., Bonfoco E., Reaves M., Huflejt M., Green D. R. Fas ligand-mediated killing by intestinal intraepithelial lymphocytes. Participation in intestinal graft-versus-host disease. Journal of Clinical Investigation 1998; 101(3)570–7
   PubMed Web of Science ®Google Scholar
• Graubert T. A., DiPersio J. F., Russell J. H., Ley T. J. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. Journal of Clinical Investigation 1997; 100(4)904–11
   PubMed Web of Science ®Google Scholar
• Nestel F. P., Price K. S., Seemayer T. A., Lapp W. S. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. Journal of Experimental Medicine 1992; 175: 405–413
   PubMed Web of Science ®Google Scholar
• Hill G. R., Crawford J. M., Cooke K. R., Brinson Y. S., Pan L., Ferrara J. L. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90(8)3204–13
   PubMed Web of Science ®Google Scholar
• Estaquier J., Ameisen J. C. A role for T-helper type-1 and type-2 cytokines in the regulation of human monocyte apoptosis. Blood 1997; 90(4)1618–25
   PubMed Web of Science ®Google Scholar
• Nishimura T., Ohta A. A critical role for antigen-specific Th1 cells in acute liver injury in mice. Journal of Immunology 1999; 162(11)6503–9
   PubMed Web of Science ®Google Scholar
• Champlin R., Ho W., Gajewski J., Feig S., Bumison M., Holley G., Greenberg P, Lee K., Schmid I., Giorgi J. Selective depletion of CD8+ T lymphocytes for prevention of graft- versus-host disease after allogeneic bone marrow transplantation. Blood 1990; 76(2)418–23
   PubMed Web of Science ®Google Scholar
• Fowler D. H., Kurasawa K., Husebekk A., Cohen P. A., Gress R. E. Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. Regulation of cytokines and CD8+ lymphoid engraftment. Journal of Immunology 1994; 152: 1004–1013
   PubMed Web of Science ®Google Scholar
• Fowler D. H., Gress R. E. GVHD as a Th1-type process: Regulation by cells of Th2 cytokine phenotype. Graft-vs-Host Disease: Immunology, Pathophysiology, and Treatment. 2^nded, S Burakoff, H J Deeg, J Ferrara, K Atkinson. Marcel Decker, Inc., New York 1996
   Google Scholar
• Krenger W., Snyder K. M., Byon J. C., Falzarano G., Ferrara J. L. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. Journal of Immunology 1995; 155: 585–593
   PubMed Web of Science ®Google Scholar
• Krenger W., Cooke K. R., Crawford J. M., Sonis S. T., Simmons R., Pan L., Demonte J., Jr., Kavandikar M., Ferrara J. L. Transplantation of polarized type 2 donor T cells reduces mortality caused by experimental graft-versus-host disease. Transplantation 1996; 62: 1278–1285
   PubMed Web of Science ®Google Scholar
• Krenger W., Snyder K., Smith S., Ferrara J. L. Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens. Transplantation 1994; 58: 1251–1257
   PubMed Web of Science ®Google Scholar
• Blazar B. R., Taylor P. A., Smith S., Vallera D. A. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood 1995; 85(3)842–51
   PubMed Web of Science ®Google Scholar
• Blazar B. R., Taylor P. A., Panoskaltsis-Mortari A., Narula S. K., Smith S. R., Roncarolo M. G., Vallera D. A. Interleukin-10 dose-dependent regulation of CD4+ and CD8+ T cell- mediated graft-versus-host disease. Transplantation 1998; 66(9)1220–9
   PubMed Web of Science ®Google Scholar
• Baker K. S., Roncarolo M. G., Peters C., Bigler M., DeFor T., Blazar B. R. High spontaneous IL-10 production in unrelated bone marrow transplant recipients is associated with fewer transplant-related complications and early deaths. Bone Marrow Transplantation 1999; 23(11)1123–9
   PubMed Web of Science ®Google Scholar
• Fowler D. H., Kurasawa K., Smith R., Eckhaus M. A., Gress R. E. Donor CD4-enriched Cells of Th2 Cytokine Phenotype Regulate Graft-versus-Host Disease Without Impairing Allogeneic Engraftment in Sublethally Irradiated Mice. Blood 1994; 84(9)3540–3549
   PubMedGoogle Scholar
• Martin P. J., Akatsuka Y., Hahne M., Sale G. Involvement of donor T-cell cytotoxic effector mechanisms in preventing allogeneic marrow graft rejection. Blood 1998; 92(6)2177–81
   PubMed Web of Science ®Google Scholar
• Halverson D., Schwartz G., Carter C., Gress R. E., Fowler D. H. In Vitro Generation of Allospecific Human CD8+ T Cells of Tel and Tc2 Phenotype. Blood 1997; 90(5)2089–2096
   PubMed Web of Science ®Google Scholar
• Qin S., Cobbold S. P., Pope H., Elliott J., Kioussis D., Davies J., Waldmann H. Infectious transplantation tolerance. Science 1993; 259: 974–977
   PubMed Web of Science ®Google Scholar
• Fowler D. H., Breglio J., Nagel G., Gress R. E. Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 Populations in Murine GVL: Type I cells generate GVL, Type II cells abrogate GVL. Biology of Blood and Marrow Transplantation 1996; 2: 118–125
   PubMedGoogle Scholar
• Hill L. L., Ouhtit A., Loughlin S. M., Kripke M. L., Anan-Thaswamy H. N., Owen-Schaub L. B. Fas ligand: a sensor for DNA damage critical in skin cancer etiology. Science 1999; 285(5429)898–900
   PubMed Web of Science ®Google Scholar
• Van den Broek M. E., Kagi D., Ossendorp F., Toes R., Vam-Vakas S., Lutz W. K., Melief C. J., Zinkernagel R. M., Hengartner H. Decreased tumor surveillance in per-forin-deficient mice. Journal of Experimental Medicine 1996; 184(5)1781–90
   PubMed Web of Science ®Google Scholar
• Barth R. J., Jr., Mule J. J., Spiess P. J., Rosenberg S. A. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. Journal of Experimental Medicine 1991; 173: 647–658
   PubMed Web of Science ®Google Scholar
• Ding L., Linsley P. S., Huang L. Y., Germain R. N., She-Vach E M. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. Journal of Immunology 1993; 151: 1224–1234
   PubMed Web of Science ®Google Scholar
• Oswald I. P., Gazzinelli R. T., Sher A., James S. L. IL-10 synergizes with IL-4 and transforming growth factor-beta to inhibit macrophage cytotoxic activity. Journal of Immunology 1992; 148: 3578–3582
   PubMed Web of Science ®Google Scholar
• Fowler D. H., Breglio J., Nagel G., Eckhaus M., Gress R. E. Allospecific CD8+ Tel and Tc2 Populations in GVL and GVHD. Journal of Immunology 1996; 157: 4811–4821
   PubMed Web of Science ®Google Scholar
• Tsukada N., Kobata T., Aizawa Y, Yagita H., Okumura K. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood 1999; 93(8)2738–47
   PubMed Web of Science ®Google Scholar
• Hill G. R., Cooke K. R., Teshima T., Crawford J. M., Keith J. C., Jr., Brinson Y. S., Bungard D., Ferrara J. L. Interleukin-11 promotes T cell polarization and prevents acute graft- versus-host disease after allogeneic bone marrow transplantation. Journal of Clinical Investigation 1998; 102(1)115–23
   PubMed Web of Science ®Google Scholar
• Teshima T., Hill G. R., Pan L., Brinson Y. S., Van den Brink M. R., Cooke K. R., Ferrara J. L. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. Journal of Clinical Investigation 1999; 104(3)317–25
   PubMed Web of Science ®Google Scholar
• Bacigalupo A., Soracco M., Vassallo F., Abate M., Van Lint M. T., Gualandi F., Lamparelli T., Occhini D., Mor-Dini N., Bregante S., Figari O., Benvenuto F, Sessarego M., Fugazza G., Carlier P., Valbonesi M., Aker M., Kapelushnik J., Pugatsch T., Naparstek E., Ben-Neria S., Yehuda O., Amar A., Nagler A., Slavin S., Or R. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplantation 1997; 19(9)927–32
   PubMed Web of Science ®Google Scholar
• Garicochea B., Van Rhee F., Spencer A., Chase A., Lin E., Cross N. C., Goldmann J. M. Aplasia after donor lymphocyte infusion (DLI) for CML in relapse after sex-mismatched BMT: recovery of donor-type haemopoiesis predicted by non-isotopic in situ hybridization (ISH). British Journal of Haematology 1994; 88(2)400–2
   PubMed Web of Science ®Google Scholar
• Gupta P., Niehans G. A., LeRoy S. C., Gupta K., Morrison V. A., Schultz C., Knapp D. J., Kratzke R. A. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival. Leukemia 1999; 13(1)44–70
   PubMed Web of Science ®Google Scholar
• Nishimura M., Uchida S., Mitsunaga S., Yahagi Y., Nakajima K., Tadokoro K., Juji T. Characterization of T-cell clones derived from peripheral blood lymphocytes of a patient with transfusion-associated graft-versus-host disease: Fas-mediated killing by CD4+ and CD8+ cytotoxic T-cell clones and tumor necrosis factor beta production by CD4+ T-cell clones. Blood 1997; 89(4)1440–5
   PubMed Web of Science ®Google Scholar
• Blazar B. R., Taylor P. A., Boyer M. W., Panoskaltsis-Mortari A., Allison J. P., Vallera D. A. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells. Journal of Immunology 1997; 159: 3460–3473
   PubMed Web of Science ®Google Scholar
• Williams J F, Petrus M J, Wright J A, Husebekk A, Fellowes V, Read E J, Gress R. E., Fowler D. H. Fas-mediated lysis of chronic lymphocytic leukaemia cells: role of type I versus type II cytokines and autologous FasL-expressing T cells. British Journal of Haematology 1999; 107
   PubMed Web of Science ®Google Scholar
• Martin P. J. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans. Journal of Experimental Medicine 1993; 118: 103–712
   Google Scholar
• Fink P. J., Shimonkevitz R. P., Bevan M. J. Veto cells. Annuual Revlmmunol. 1988; 6: 115–137
   Google Scholar
• Hiruma K., Nakamura H., Henkart P. A., Gress R. E. Clonal deletion of postthymic T cells: veto cells kill precursor cytotoxic T lymphocytes. Journal of Experimental Medicine 1992; 175: 863–868
   PubMed Web of Science ®Google Scholar
• George J. F., Thomas J. M. The molecular mechanisms of veto mediated regulation of alloresponsiveness. Journal of Molecular Medicine 1999; 77(7)519–26
   PubMed Web of Science ®Google Scholar
• Nakamura H., Gress R. E. Interleukin 2 enhancement of veto suppressor cell function in T-cell-depleted bone marrow in vitro and in vivo. Transplantation 1990; 49: 931–937
   PubMed Web of Science ®Google Scholar
• Martin P. J. Prevention of allogeneic marrow graft rejection by donor T cells that do not recognize recipient alloantigens: potential role of a veto mechanism. Blood 1996; 88: 962–969
   PubMed Web of Science ®Google Scholar
• Bachar-Lustig E., Li H. W., Marcus H., Reisner Y. Tolerance induction by megadose stem cell transplants: synergism between SCA-1+ Lin- cells and nonallore-active T cells. Transplant Proceedings 1998; 30(8)4007–8
   PubMed Web of Science ®Google Scholar
• Fowler D., Whitfield B., Livingston M., Chrobak P., Gress R. E. Non-host reactive donor CD8+ T cells of Tc2 phenotype potently inhibit marrow graft rejection. Blood 1998; 91(11)4045–4050
   PubMed Web of Science ®Google Scholar
• Mavroudis D. A., Dermime S., Molldrem J., Jiang Y. Z., Raptis A., Van Rhee F., Hensel N., Fellowes V, Eliopoulos G., Barrett A. J. Specific depletion of allore-active T cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reactions. British Journal of Haematology 1998; 101(3)565–70
   PubMed Web of Science ®Google Scholar
• Guinan E. C., Boussiotis V. A., Neuberg D., Brennan L. L., Hirano N., Nadler L. M., Gribben J. G. Transplantation of anergic histoincompatible bone marrow allografts. New England Journal of Medicine 1999; 340(22)1704–14
   PubMed Web of Science ®Google Scholar
• Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, De Vries J E, Roncarolo M. G. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389(6652)737–42
   PubMed Web of Science ®Google Scholar
• Sallusto F., Lanzavecchia A., Mackay C. R. Chemokines and chemokine receptors in T-cell priming and Th1/Th2- mediated responses. Immunology Today 1998; 19(12)568–74
   PubMedGoogle Scholar